Journal
ORGANIC PROCESS RESEARCH & DEVELOPMENT
Volume 25, Issue 3, Pages 608-615Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.oprd.0c00366
Keywords
process chemistry; Curtius rearrangement; Lossen rearrangement; biocatalysis; JAK inhibitor; Pfizer
Categories
Ask authors/readers for more resources
The development of a commercial route towards the JAK1 inhibitor abrocitinib involves a late-stage Lossen rearrangement to obtain the desired compound, which is then sulfonylated using a novel water-tolerable triazole sulfonylating reagent to provide the active pharmaceutical ingredient.
The development of a commercial route toward the JAK1 inhibitor abrocitinib is described. The application of a late-stage Lossen rearrangement provided the desired cis-diaminocyclobutane, which was subsequently sulfonylated using a novel water-tolerable triazole sulfonylating reagent to provide the active pharmaceutical ingredient.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available